ClinicalTrials.gg
WithdrawnNCT04177303INCREDIBLE-MUpdated Nov 3, 2026

Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment

A Phase 3 interventional study of Metformin and Placebo in Type 1 Diabetes Mellitus, sponsored by Hellenic Institute for the Study of Sepsis. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hellenic Institute for the Study of Sepsis · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
It was not conducted due to the emergency restrictive measures implemented during the COVID-19 pandemic, which made it impossible to carry out the patient visits required by the study protocol.
Updated Nov 3, 2026Now WithdrawnNo longer in Greece+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing metformin in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. Metformin · Diabetes Mellitus, Type 1.

Enrollment
21st of 22
0 · median 43
Started
2019
with 2 others
Phase 3
7 of 22
none open now
Registered
17th of 22
by date
Lead sponsor
1 of 22
Hellenic Institute for the Study of Sepsis

Among the 22 studies testing metformin in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is one of 3 that started in 2019, is one of 7 in phase 3, and was the 17th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 22 studies testing metformin in Diabetes Mellitus, Type 1 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing metformin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Investigators aim is to conduct an RCT to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion. The patients will be randomly allocated to metformin or placebo treatment for 4 months

Read the detailed description

Compared to the large armamentarium of antidiabetic agents for Type 2 Diabetes Mellitus (T2DM), the insulinocentric therapeutic approach in Type 1 Diabetes Mellitus (T1DM) has distracted the scientific perspective from the rise of novel therapies. Insulin monotherapy has long overshadowed the overall hormonal dysregulation that demarcates T1DM . In specific, the significance of the gut-derived incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide), which are implicated with glucose metabolism via the gut-pancreatic axis, has been merely addressed.

Investigators' goal in the current protocol is to delineate the glucoregulatory role of incretin hormones in T1DM and the therapeutic advantages of adjunct metformin treatment over insulin monotherapy. In the absence of such knowledge, the development of effective strategies to improve metabolic homeostasis and ameliorate complications in T1DM patients will remain problematic. The central hypothesis of the study is that metformin, as an incretin-secretagogue, will enhance postprandial incretin secretion in T1DM patients, which will be reflected in reduced glucagon secretion and improvement in glycemic volatility. Mechanistic insight will be provided through changes in specific amino acids and metabolites patterns, chronic inflammation and the microbiome composition.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Metformin
  • Incretin hormones
  • Inflammation
  • Microbiome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • T1DM (Diagnosis of diabetes before the age of 35 years and insulin use within 1 year of diagnosis)
  • Treatment with multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII)

Exclusion criteria

Exclusion Criteria:

  • Any cardiovascular disease within the last 3 months
  • stage 3 or 4 heart failure
  • Uncontrolled angina
  • Liver failure [>135 IU/L or ALT>129IU/L (3 x the upper normal limit)] • Kidney failure or \<60 ml/min/1.73m2
  • Gastrointestinal disease or gastroparesis
  • Prior diagnosis of cancer within 2 years
  • Other medication that affect glucose metabolism within the last 3 months (metformin, SGLT2, GLP-1 analogues, amylin analogues, systemic glucocorticosteroids)
  • Untreated or uncontrolled thyroid disease
  • Pregnancy or breastfeeding
  • Alcohol consumption > 2-drinks per day or other substance abuse
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Metformin

    Patients will continue with their standard insulin therapy and will additionally receive orally metformin 2gr/day.

    Drug: Metformin

  • Placebo comparator
    Placebo

    Patients will continue with their standard insulin therapy and will additionally receive placebo

    Drug: Placebo

Interventions

  • Participants will be randomized to metformin 2000 mg

  • DrugPlacebo

    Participants will be randomized to placebo

06

What researchers measure

Primary outcomes

  1. Change in GLP-1 (glucagon like peptide) and GIP (gastric inhibitory peptide) postprandial secretion

    The primary endpoint of the study is the change in postprandial GLP-1(ng/ml) and GIP (ng/ml) secretion with metformin treatment compared to placebo.

    Time frame: 4 months

Secondary outcomes

  1. Change in glycemic variability pre- and post- treatment

    A continuous glucose-monitoring device will be attached to each participant and record daily glucose measurements (mg/dl) for 6 consecutive days on two separate time points: a) within a week prior to randomization and b) as a follow up, within a week prior to Inpatient Visit 2.

    Time frame: 4 months

  2. Metabolomic profile of each treatment group

    Untargeted metabolomics analysis and identification of candidate metabolites using mass spectrometry. Quantitative targeted metabolomics will then be applied on candidate metabolites to compare differences pre and post treatment between metformin and placebo treatment arm

    Time frame: 4 months

  3. Change in inflammatory state

    Corrrelation of CRP levels (mg/dl) and treatment arm, as marker of inflammation. CRP will be measured from plasma blood samples collected during Inpatient Visits 1 and 2.

    Time frame: 4 months

  4. Change in endothelial dysfunction

    Correlation of Serpin E1/PAI-1 levels (ng/ml), VEGF levels (pg/ml), ICAM1 levels (ng/ml) SYndecan-1 levels (ng/ml) and placebo/metformin administration, as markers of endothelial dysfunction. Concentration of adhesion molecules will be measured and compared from plasma blood samples collected during Inpatient Visits 1 and 2.

    Time frame: 4 months

  5. Change in cytokine production

    Correlation of TNFα levels (pg/ml) ,IL-6 levels (pg/ml),IL-1β levels (pg/ml),IL-10 levels ,(pg/ml) and placebo/metformin administration, as markers of inflammation. Concentration of cytokines will be measured and compared from plasma blood samples collected during Inpatient Visits 1 and 2.

    Time frame: 4 months

  6. Change in matrix metalloproteinase-9 (MMP-9) levels

    Correlation of MMP-9 levels (ng/ml) levels and placebo/metformin administration, as markers of inflammation. Concentration of MMP-9 will be measured and compared from plasma blood samples collected during Inpatient Visits 1 and 2.

    Time frame: 4 months

  7. Change in chemokine production

    Correlation of CCL2 levels (pg/ml) ,CCL3 levels (pg/ml),CCL4 levels (pg/ml) and placebo/metformin administration, as markers of inflammation. Concentration chemokines will be measured and compared from plasma blood samples collected during Inpatient Visits 1 and 2.

    Time frame: 4 months

  8. Change in gene expression

    RNA from PBMCs collected pre and post intervention will be isolated and Quantitative Real Time PCR will be used to measure the transcription of genes related to inflammation and endothelial function.

    Time frame: 4 months

  9. Change in gut microbiome analysis

    Stool samples will be collected pre and post the intervention on Inpatient Visits 1 and 2 to identify the changes in the microbiome composition based on phylogenetic analysis of the 16S rRNA gene sequencing classification using quantitative PCR.

    Time frame: 4 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2019 to primary completion in Dec 2024, 61 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Nov 2022 → Dec 2024 and completion Nov 2022 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2019
First posted
Nov 26, 2019
StartActual
Nov 29, 2019
Primary completionActual
Dec 31, 2024was Nov 2022
CompletionActual
Dec 31, 2024was Nov 2022
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Withdrawn It was not conducted due to the emergency restrictive measures implemented during the COVID-19 pandemic, which made it impossible to carry out the patient visits required by the study protocol.
changed Nov 3, 2026
Sites
1 site removed; no longer in Greece
Show 1 removed
  • Diabetes Center, 1st Internal Medicine Department, AHEPA University General Hospital of Thessaloniki · Thessaloníki, Greece
Nov 3, 2026
Primary completion
Nov 29, 2022→Dec 31, 2024 (actual)
Nov 3, 2026
Study completion
Nov 29, 2022→Dec 31, 2024 (actual)
Nov 3, 2026
Enrollment
44 (estimated)→0 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Status unknown→Withdrawn
    Why stopped It was not conducted due to the emergency restrictive measures implemented during the COVID-19 pandemic, which made it impossible to carry out the patient visits required by the study protocol.
    1 site removed; no longer in Greece
    Show 1 removed
    • Diabetes Center, 1st Internal Medicine Department, AHEPA University General Hospital of Thessaloniki · Thessaloníki, Greece
    Primary completion Nov 29, 2022→Dec 31, 2024 (now actual)
    Study completion Nov 29, 2022→Dec 31, 2024 (now actual)
    Enrollment 44 (estimated)→0 (actual)
    + 2 other changes: contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04177303
Lead sponsor
Hellenic Institute for the Study of Sepsis
Responsible party
Sponsor
First posted
Nov 26, 2019
Start date
Nov 29, 2019
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Nov 3, 2026

Study contacts

Kotsa Kalliopi, MD,PhD
principal investigator · 1st Internal Medicine Department, AHEPA University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion